Deadline 15. april


The organizing committee cordially invites you to submit your abstract for the 21st International Congress of the IATDMCT to be held in Oslo September 24-27, 2023.

Submit now!

All abstracts must be submitted electronically only through this website. Abstracts submitted via e-mail or regular mail will neither be accepted nor acknowledged.

Deadline for submitting abstract: 15. April 2023.

All submitted abstracts will be peer-reviewed and assigned to appropriate session. Notification on acceptance will be sent to the submitter by email by early June 2023. Accepted contributions will be selected into two groups for presentation; poster or oral presentation.

Specific topics for include, but are not limited to:

  • Immunosuppression
  • Anti-infectives - antivirals
  • Anti-infectives - antibiotics and antifungals
  • Oncology
  • Biologicals
  • Psychiatry
  • Clinical toxicology and drugs of misuse
  • Toxicology and environmental health
  • Alternative sampling strategies
  • Pharmacogenetics
  • Pharmacometrics
  • Micellanous

Guidelines for submitting an abstract

If accepted for poster or oral presentation, the presenting author should register for the conference by June 15th to benefit from the Early Bird price. If the presenter does not register, the presentation will be cancelled.


The conference language is English, and abstract submission is possible in English only.
Indicate if you prefer poster presentation. Otherwise, the scientific committee will decide whether your paper will be accepted as an oral presentation or poster.

Please note that only the submitting (corresponding) author receives all abstract notifications. Make sure that emails from IATDMCT@gyro.no are not marked as spam by your email provider.
The submitting (corresponding) author takes responsibility for informing all co-authors about successful submission, acceptance or rejection and forwards the received instructions for the presentation of the abstract to the presenting author.

Abstract contents and format

Do not use the title or the name(s) of the author(s) in the body of the abstract.
Please organize the abstract as follows:

  1. Introduction
  2. Materials and Methods
  3. Results
  4. Discussions and Conclusions

Maximum length of the abstract is max. 500 words.
Use text only in the abstract, do not include images or tables. Please use a minimum of formatting for abstracts. We cannot guarantee that abstracts will be formatted in the exact way as they are entered.

All submissions will be peer reviewed.
Avoid using non-standard abbreviations or define them when they first appear in the text.

Abstract will be published on the website of the TDM Journal

Therapeutic Drug Monitoring is a peer-reviewed, multidisciplinary journal directed to an audience of pharmacologists, clinical chemists, laboratorians, pharmacists, drug researchers and toxicologists. It fosters the exchange of knowledge among the various disciplines–clinical pharmacology, pathology, toxicology, analytical chemistry–that share a common interest in Therapeutic Drug Monitoring. The journal presents studies detailing the various factors that affect the rate and extent drugs are absorbed, metabolized, and excreted. Therapeutic Drug Monitoring is interested in clinical studies that assess and establish pharmacokinetics/pharmacodynamics or toxicokinetics/toxicodynamics relationships. Regular features include review articles on specific classes of drugs, original articles, case reports, technical notes, and continuing education articles. Therapeutic Drug Monitoring is the official Journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.